What Are Peptides?

Peptides are short chains of amino acids - typically between 2 and 50 residues - linked by peptide bonds. They sit at the intersection of simplicity and specificity: small enough to be synthesised with precision, complex enough to interact with biological systems through highly targeted receptor binding.

Found in every living organism, peptides function as signalling molecules, regulators, and mediators. They are involved in immune response, cellular communication, metabolic regulation, tissue repair, and hormonal control. Their ubiquity in biology is what makes them such a compelling subject for scientific investigation.

How Peptides Are Built

A peptide forms when amino acids are joined through peptide bonds - a covalent linkage between the carboxyl group of one amino acid and the amino group of the next. This chain folds into specific three-dimensional conformations that determine how the peptide interacts with its biological environment.

The distinction between peptides and proteins is largely one of size. Chains shorter than approximately 50 amino acids are classified as peptides; longer chains are considered proteins. This boundary is not rigid - some researchers use different thresholds - but it serves as a useful framework. Many biologically active peptides fall well below this threshold, with significant regulatory molecules containing as few as 3 to 10 amino acid residues.

The sequence, length, and folding pattern of a peptide determine its function. A single amino acid substitution can dramatically alter receptor affinity, metabolic stability, and biological activity. This specificity is what makes peptides both powerful research tools and subjects of ongoing investigation.

What Peptides Do in the Body

Peptides operate across an extraordinary range of biological systems. They act as hormones (insulin regulates glucose metabolism), neuropeptides (endorphins modulate pain signalling), antimicrobial agents (defensins form part of innate immunity), and growth factors (GHK-Cu influences tissue remodelling processes).

Unlike larger proteins, many peptides can cross cell membranes or interact with membrane-bound receptors directly, enabling rapid and targeted signalling. This makes them particularly relevant to researchers studying cellular communication, receptor pharmacology, and intercellular signalling cascades.

Key areas of peptide function in biological systems include:

Metabolic regulation - Incretin hormones such as GLP-1 and GIP are peptides that modulate insulin secretion and appetite signalling. Their pathways have become a major focus of metabolic research.

Immune modulation - Thymosin alpha-1 and related peptides are studied for their role in immune cell differentiation and inflammatory response regulation.

Cellular repair - Peptides like BPC-157 and TB-500 are investigated for their involvement in cellular recovery and tissue maintenance processes in preclinical models.

Neuroendocrine signalling - Peptides such as kisspeptin and gonadorelin act on the hypothalamic-pituitary axis, influencing reproductive and endocrine function at the research level.

ENDOGENOUS NATURE

Naturally Occurring, Difficult to Patent

One of the defining characteristics of peptides is that most are endogenous - they occur naturally in the human body and throughout the biological world. This is not a minor footnote. It has significant implications for how peptide research is conducted, shared, and built upon.

Because naturally occurring peptide sequences cannot be claimed as novel compositions of matter, they are inherently more difficult to patent than synthetic small-molecule compounds. While modified analogues and delivery mechanisms may receive patent protection, the core peptide sequences themselves often remain in the public domain. This creates a more open research landscape - one where scientific progress is not locked behind proprietary barriers to the same degree as other areas of pharmacology.

This openness has contributed to the rapid growth of peptide science. Researchers can investigate endogenous sequences without navigating the same intellectual property constraints that govern synthetic drug development. The result is a field characterised by broad collaboration, reproducibility, and a growing body of publicly available data from preclinical and clinical studies.

RESEARCH METHODS

How Peptides Are Studied

Peptide research spans a spectrum from in vitro biochemical assays to large-scale human clinical trials. The methodological approach depends on the research question, the peptide under investigation, and the stage of the scientific programme.

Solid-phase peptide synthesis (SPPS) is the dominant method for producing research-grade peptides. Developed by Robert Merrifield in the 1960s, SPPS allows amino acids to be added sequentially to a growing chain anchored to an insoluble resin. This approach enables precise control over sequence, purity, and modifications - essential for reproducible research.

Lyophilisation (freeze-drying) is the standard method for stabilising synthesised peptides. By removing water under controlled vacuum conditions, lyophilised peptides achieve extended shelf stability without the need for temperature-controlled storage or transport. This is a significant practical advantage for researchers working across distributed laboratory environments.

Analytical testing is used to verify the identity, purity, and composition of synthesised peptides. Techniques such as mass spectrometry and chromatographic analysis provide researchers with the characterisation data necessary to ensure experimental integrity. Certificates of analysis are typically available for research-grade compounds.

CLINICAL TRIALS

From Laboratory to Clinical Investigation

Peptides occupy a unique position in the drug development pipeline. Their endogenous origin means that many peptide sequences have already been validated by biology itself - the human body produces them, processes them, and responds to them through established receptor systems. This provides a rational starting point for clinical investigation that purely synthetic compounds may lack.

The clinical trial pathway for peptide-based research follows the standard regulatory framework:

Phase 1 - Small studies to evaluate safety, dosing, and pharmacokinetics in a controlled population.

Phase 2 - Larger studies to assess biological activity, optimal dosing, and preliminary efficacy signals.

Phase 3 - Large-scale, multi-site trials designed to confirm efficacy and monitor adverse effects across diverse populations.

Phase 4 - Post-approval monitoring and long-term safety data collection.

Several peptide-based compounds have advanced through these stages in recent years. GLP-1 receptor agonists, originally studied for metabolic pathways, are now among the most widely investigated drug classes globally. Triple agonists engaging GLP-1, GIP, and glucagon receptors simultaneously represent the next frontier of metabolic research, with multiple candidates in late-stage trials.

The growing volume of clinical trial data - much of it publicly accessible through registries such as ClinicalTrials.gov - continues to expand the scientific community's understanding of peptide biology and its potential applications.